Business Wire

Toshiba Electronic Devices & Storage to Unveil Low Voltage 5GHz Receiver for Next-Generation Wireless LAN

Del

Toshiba Electronic Devices & Storage Corporation (TDSC) today announced development of a low voltage 5GHz receiver for the next-generation IEEE802.11ax1 wireless LAN. The company reported details of the technology on September 14th at the European Solid-State Circuits Conference in Belgium.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170915005376/en/

Fig. 1 : Variable linearity RFAMP (Graphic: Business Wire)

Fig. 1 : Variable linearity RFAMP (Graphic: Business Wire)

Continued growth in the Internet of Things requires high-speed communications in environments increasingly crowded with numerous wireless LAN devices. IEEE 802.11ax, the next-generation wireless LAN, will be four times faster than its predecessor, even in crowded environments. However, high speed digital signal processing with low power dissipation requires adoption of a faster CMOS devices, operating with supply voltages lower than 1.0V. Unlike digital circuits, the performance of CMOS analog circuits, such as RF2 CMOS receivers, degrades drastically as voltage falls. New circuit technology that can operate below 1.0V is required to overcome this problem.

TDSC has developed three new technologies for low voltage RF receivers.
The first is a variable linearity RF amplifier (RFAMP). Since signal amplitude is affected by power supply voltage, the linearity of RFAMPs decreases as voltage falls. Conventional RFAMP uses variable resistance to improve the linearity, but internal DC voltage and amplifier performance are also changed by adjusting the resistor value. In order to avoid these problems, Toshiba’s new RFAMP simultaneously employs two input paths: a high linearity path and an internal voltage adjustment path. The RFAMP can adjust linearity without any change in the internal DC voltage.

The second is a low noise frequency converter. A frequency converter switches a received RF signal into a low frequency signal to input into the analog to digital converter. Conventional frequency converters use a DC current source to improve the performance of conversion switches in low voltage designs, but this additional current source degrades performance with low frequency noise. Toshiba’s new frequency converter suppresses low frequency noise by moving the DC current source to the RF side of the conversion switches. Low frequency noise is up-converted to the RF frequency, which is separated from the desired low frequency signal. The result is sufficient switch performance without noise degradation.

The third is a current adder OPAMP. The OPAMP amplifies the converted low frequency signal to level a sufficient high to input the analog signal into the digital converter. Since the maximum output signal level is limited by the supply voltage, OPAMP is forced to reduce its operating voltage range. The new OPAMP suppresses the DC current source from the output stage with a high speed differential current mirror3, and provides larger output voltage even in a low voltage environment. .

Integrating these three technologies into a 5GHz wireless LAN receiver has allowed TDSC to secure the level of performance essential for next-generation wireless LAN.

TDSC will continue to develop the transceiver, and to contribute to the progress of high speed wireless communication.

Notes

[1]   IEEE 802.11ax operates at frequencies of 2.4 and 5 GHz. It will improve average throughput in environments with high terminal densities.
[2] RF: Radio Frequency.
[3] High speed differential current mirror: A high speed circuit designed to copy a current from inputs to outputs by the designated factor. A stacked MOSFET is used to improve speed in the circuit.
 

About Toshiba Electronic Devices & Storage Corporation
Toshiba Electronic Devices & Storage Corporation (TDSC) combines the vigor of a new company with the wisdom of experience. Since being spun off from Toshiba Corporation in July 2017, we have taken our place among the leading general devices companies, and offer our customers and business partners outstanding solutions in discrete semiconductors, system LSIs and HDD.

Our 19,000 employees around the world share a determination to maximize the value of our products, and emphasize close collaboration with customers to promote co-creation of value and new markets. We look forward to building on annual sales now surpassing 700-billion yen (US$6 billion) and to contributing to a better future for people everywhere.
Find out more about us at https://toshiba.semicon-storage.com/ap-en/company.html

Contact information

Press Contact:
Toshiba Electronic Devices & Storage Corporation
Motohiro Ajioka
Public Relations & Investor Relations Group
Business Plannning Division
Tel +81-3-3457-3576
Fax +81-3-5444-9339
motohiro1.ajioka@toshiba.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31Pressemelding

Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00Pressemelding

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20Pressemelding

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11Pressemelding

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20Pressemelding

Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to

Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31Pressemelding

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom